Literature DB >> 20699743

Global differences in causes, management, and survival after severe trauma: the recombinant activated factor VII phase 3 trauma trial.

Michael C Christensen1, Michael Parr, Bartholomew J Tortella, Johan Malmgren, Stephen Morris, Todd Rice, John B Holcomb.   

Abstract

BACKGROUND: Little is known about international variation in mortality after severe trauma. This study examines variation in mortality, injury severity, and case management among countries from a recent prospective multinational trauma trial.
METHODS: This trauma trial was a prospective, randomized, double-blinded, multicenter comparison of recombinant activated factor VII versus placebo in severely injured bleeding trauma patients. Differences in baseline patient characteristics, case management, and clinical outcomes were examined for the 11 countries recruiting most patients. Between-country differences in mortality were examined using regression analysis adjusting for case mix and case management differences. Global predictors of mortality were also identified using multivariate regression analysis.
RESULTS: Significant differences were observed between countries in unadjusted mortality rates at 24 hours (p = 0.025) and 90 days (p < 0.0001). When adjusting for differences in case mix and case management, the between country differences in mortality at 24 hours and 90 days remained significant. Consistent independent predictors of 24-hour, 24-hour to 90-day, and 90-day mortality were admission lactate >or=5 mmol/L (odds ratio: 9.06, 3.56, and 5.39, respectively) and adherence to clinical management guidelines (odds ratio: 4.92, 5.90, and 3.26, respectively). On average, the damage control surgery guideline was less well adhered to than the RBC transfusion and ventilator guidelines. There was statistically significant variation between countries with respect to adherence to the RBC transfusion guideline.
CONCLUSIONS: Considering international variation in mortality when designing or interpreting results from multinational trauma studies is important. Significant differences in mortality persisted between patients from different countries after case mix and case management adjustment. Adherence to clinical guidelines was associated with improved survival. Stratification, case mix adjustment, and use of guidelines on damage control surgery, transfusion, and ventilation may mitigate country-driven variation in mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20699743     DOI: 10.1097/TA.0b013e3181e74c69

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  4 in total

1.  Practice management of acute trauma haemorrhage and haemostatic disorders across German trauma centres.

Authors:  V Albrecht; N Schäfer; E K Stürmer; A Driessen; L Betsche; M Schenk; M Maegele
Journal:  Eur J Trauma Emerg Surg       Date:  2015-11-30       Impact factor: 3.693

2.  Changes in the outcomes of severe trauma patients from 15-year experience in a Western European trauma ICU of Emilia Romagna region (1996-2010). A population cross-sectional survey study.

Authors:  Salomone Di Saverio; Giorgio Gambale; Federico Coccolini; Fausto Catena; Eleonora Giorgini; Luca Ansaloni; Niki Amadori; Carlo Coniglio; Aimone Giugni; Andrea Biscardi; Stefano Magnone; Filippo Filicori; Piergiorgio Cavallo; Silvia Villani; Francesco Cinquantini; Massimo Annicchiarico; Giovanni Gordini; Gregorio Tugnoli
Journal:  Langenbecks Arch Surg       Date:  2013-11-30       Impact factor: 3.445

3.  Establishing a trauma registry in Bhutan: needs and process.

Authors:  Stephen C Morris; Nicolas Manice; Taylor Nelp; Tashi Tenzin
Journal:  Springerplus       Date:  2013-05-20

4.  Early hospital mortality among adult trauma patients significantly declined between 1998-2011: three single-centre cohorts from Mumbai, India.

Authors:  Martin Gerdin; Nobhojit Roy; Satish Dharap; Vineet Kumar; Monty Khajanchi; Göran Tomson; Li Felländer Tsai; Max Petzold; Johan von Schreeb
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.